GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Goodwill

Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Goodwill : $0.0 Mil (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Arrowhead Pharmaceuticals's goodwill for the quarter that ended in Dec. 2023 was $0.0 Mil.


Arrowhead Pharmaceuticals Goodwill Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Goodwill Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Goodwill
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arrowhead Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Arrowhead Pharmaceuticals Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Arrowhead Pharmaceuticals  (NAS:ARWR) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Arrowhead Pharmaceuticals's Goodwill-to-Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Goodwill-to-Asset (A: Sep. 2023 )=Goodwill/Total Assets
=0/765.552
=0.00

Arrowhead Pharmaceuticals's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Goodwill-to-Asset (Q: Dec. 2023 )=Goodwill/Total Assets
=0/626.286
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Arrowhead Pharmaceuticals Goodwill Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Executives
James C Hamilton other: Senior Vice President 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mauro Ferrari director 201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Tracie Oliver officer: Chief Commercial Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Patrick O'brien officer: General Counsel 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San officer: Chief Medical Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Kenneth Allen Myszkowski officer: CFO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone director, officer: President and CEO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105